Recurrent Marginal Zone Lymphoma: Clinical Trials

83 trials for Recurrent Marginal Zone Lymphoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

51 completed, 18 terminated, 8 active not recruiting, 5 withdrawn. 83 Phase 1, 22 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 183Completed 51, Terminated 18, Active not recruiting 8, Withdrawn 5, Recruiting 1
Phase 222Completed 13, Terminated 5, Active not recruiting 2, Withdrawn 2

Follow Recurrent Marginal Zone Lymphoma: new trials by email Literature Review of Recurrent Marginal Zone Lymphoma trials Research Report on Recurrent Marginal Zone Lymphoma

Trials (filtered) newest first · largest first

All 83 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies
Autologous BAFFR-targeting CAR T Cells, Bendamustine, Biopsy - B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia
Phase 1RecruitingMayo Clinic272024-03-182026-02-13
Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
Lenalidomide, Ublituximab, Umbralisib - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
Phase 1WithdrawnYazeed Sawalha2022-09-302022-09-30
Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
Acalabrutinib, Duvelisib - Recurrent Follicular Lymphoma, Recurrent Marginal Zone Lymphoma
Phase 1WithdrawnNarendranath Epperla2022-07-012022-06-07
CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL
CpG-STAT3 siRNA CAS3/SS3, Radiation Therapy - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma
Phase 1WithdrawnCity of Hope Medical Center2021-07-272024-04-25
CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma
Lenalidomide, Obinutuzumab, Oral Azacitidine - Indolent B-Cell Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma
Phase 1CompletedJoseph Tuscano82020-10-232025-04-24
An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment
Venetoclax, Lenalidomide, Rituximab - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Follicular Lymphoma
Phase 1Active not recruitingThomas Jefferson University42020-10-162026-10-02
Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma
Carmustine, Cytarabine, Etoposide - Hematopoietic Cell Transplantation Recipient, Recurrent Diffuse Large B-Cell Lymphoma
Phase 1 / Phase 2CompletedOhio State University Comprehensive Cancer Center192018-09-102025-05-14
Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma
Ibrutinib, Laboratory Biomarker Analysis, Pevonedistat - B-Cell Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia
Phase 1CompletedCity of Hope Medical Center182018-04-272026-11-10
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Laboratory Biomarker Analysis - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia
Phase 1 / Phase 2Active not recruitingFred Hutchinson Cancer Center532017-12-052026-06-22
Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma
Cryosurgery, Dendritic Cell Therapy, Laboratory Biomarker Analysis - Aggressive Non-Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma
Phase 1 / Phase 2CompletedMayo Clinic112017-08-152026-05-04
Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma
Selinexor - Diffuse Large B-Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma
Phase 1 / Phase 2Active not recruitingBarbara Ann Karmanos Cancer Institute432017-06-202026-10-23
Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Lenalidomide, Obinutuzumab, Venetoclax - B-Cell Lymphoma, Unspecified, Grade 1 Follicular Lymphoma
Phase 1Active not recruitingBeth Christian222017-02-212026-09-24
Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma
Laboratory Biomarker Analysis, Lenalidomide, Nivolumab - Grade 3a Follicular Lymphoma, Recurrent Burkitt Lymphoma
Phase 1 / Phase 2CompletedDavid Bond, MD362017-02-142026-09-23
Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Ibrutinib, Laboratory Biomarker Analysis, Pembrolizumab - B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma, Grade 1 Follicular Lymphoma
Phase 1CompletedKami Maddocks22017-01-122019-07-30
Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma
Blinatumomab, Lenalidomide - Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma
Phase 1CompletedNational Cancer Institute (NCI)352016-11-152025-11-26
Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma
rituximab, lenalidomide, romidepsin - B-cell Adult Acute Lymphoblastic Leukemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Phase 1 / Phase 2WithdrawnMayo Clinic2016-10-012016-08-11
CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
6,8-bis(benzylthio)octanoic acid, bendamustine hydrochloride, rituximab - B-cell Adult Acute Lymphoblastic Leukemia, B-cell Chronic Lymphocytic Leukemia
Phase 1TerminatedWake Forest University Health Sciences12014-12-012018-07-02
Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia
Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes, Bendamustine Hydrochloride, Cyclophosphamide - B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, B-Cell Prolymphocytic Leukemia
Phase 1Active not recruitingCity of Hope Medical Center372014-10-142026-10-26
A Phase I/II Study of Intratumoral Injection of SD-101
Ipilimumab, SD-101, Radiation therapy - Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma
Phase 1 / Phase 2CompletedRobert Lowsky92014-09-012019-11-27
Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection
Ibrutinib, Laboratory Biomarker Analysis, Pharmacological Study - Adult B Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia
Phase 1TerminatedNational Cancer Institute (NCI)722014-09-012015-08-20

Showing 20 of 83. Sign in to see all of them.

Narrower conditions

Lymphoma, B-Cell, Marginal Zone (83)  ·  Lymphoma, Follicular (82)  ·  Lymphoma, Mantle-Cell (73)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (67)  ·  Lymphoma, Large B-Cell, Diffuse (65)  ·  Lymphoma, Non-Hodgkin (59)  ·  Waldenstrom Macroglobulinemia (57)  ·  Burkitt Lymphoma (53)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (49)  ·  Lymphoma, Large-Cell, Immunoblastic (44)  ·  Hodgkin Disease (34)  ·  Lymphoma, Large-Cell, Anaplastic (34)  ·  Mycosis Fungoides (34)  ·  Sezary Syndrome (34)  ·  Lymphoma, T-Cell, Cutaneous (33)

Broader conditions

Hemic and Lymphatic Diseases (83)  ·  Immune System Diseases (83)  ·  Immunoproliferative Disorders (83)  ·  Lymphatic Diseases (83)  ·  Lymphoma (83)  ·  Lymphoproliferative Disorders (83)  ·  Neoplasms (83)  ·  Neoplasms by Histologic Type (83)  ·  Hematologic Diseases (77)  ·  Lymphoma, B-Cell (72)  ·  Leukemia (68)  ·  Chronic Disease (67)  ·  Disease Attributes (67)  ·  Leukemia, B-Cell (67)  ·  Leukemia, Lymphoid (67)

Interventions

Rituximab (18)  ·  Lenalidomide (13)  ·  fludarabine phosphate (9)  ·  Bortezomib (8)  ·  Bendamustine Hydrochloride (6)  ·  Cyclophosphamide (5)  ·  Vorinostat (5)  ·  ibrutinib (5)  ·  tanespimycin (5)  ·  Flow Cytometry (4)  ·  Peripheral Blood Stem Cell Transplantation (4)  ·  Biopsy (3)  ·  CTLA-4 Antigen (3)  ·  Cyclosporine (3)  ·  Etoposide (3)

Sponsors

National Cancer Institute (NCI) (43)  ·  Fred Hutchinson Cancer Center (7)  ·  City of Hope Medical Center (6)  ·  Mayo Clinic (5)  ·  Case Comprehensive Cancer Center (2)  ·  Kami Maddocks, MD (2)  ·  Robert Lowsky (2)  ·  Amir Mortazavi (1)  ·  Barbara Ann Karmanos Cancer Institute (1)  ·  Beth Christian (1)  ·  David Bond, MD (1)  ·  Joseph Tuscano (1)  ·  Kami Maddocks (1)  ·  M.D. Anderson Cancer Center (1)  ·  Morphotek (1)

Countries

United States (78)  ·  Canada (4)  ·  Italy (2)  ·  Germany (1)

Top investigators

Kami Maddocks, MD (4)  ·  Ajay Gopal (3)  ·  John Byrd (2)  ·  Joseph M Tuscano (2)  ·  Patricia LoRusso (2)  ·  Ramesh Ramanathan (2)  ·  Tanya Siddiqi (2)  ·  Thomas Witzig (2)  ·  Adam Petrich, MD (1)  ·  Alexey Danilov (1)  ·  Amir Mortazavi, MD (1)  ·  Antonius Miller (1)  ·  Beth A Christian (1)  ·  Beth Christian, MD (1)

Results publications

PMID 32499241, PMID 34515338, PMID 22259028, PMID 22308288, PMID 23256542, PMID 24241210, PMID 24474568, PMID 24530971, PMID 25355819, PMID 26943915, PMID 27118452, PMID 28270022, PMID 28314788, PMID 29292843, PMID 29572391, PMID 31388792, PMID 31617432, PMID 33492438, PMID 33785483, PMID 34320785, PMID 34492703, PMID 34780125, PMID 36631449, PMID 39161543

NIH funding

U01CA076576 (9), P30CA015083 (5), P30CA016058 (5), U01CA062487 (5), U01CA062491 (5), U01CA062505 (5), U01CA099168 (5), U01CA062502 (4), P30CA015704 (3), P30CA033572 (3), P50CA107399 (3), U01CA069912 (3), U01CA132123 (3), P01CA044991 (2), P30CA022453 (2)